European Journal of Clinical Pharmacology

, Volume 30, Issue 2, pp 191–194

Fenofibrate and colestipol: Effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia

  • P. Weisweiler
  • W. Merk
  • B. Jacob
  • P. Schwandt
Article

DOI: 10.1007/BF00614301

Cite this article as:
Weisweiler, P., Merk, W., Jacob, B. et al. Eur J Clin Pharmacol (1986) 30: 191. doi:10.1007/BF00614301

Summary

Effects on serum lipoproteins were studied in ten patients with familial hypercholesterolaemia (FH) during consecutive eight-week treatment periods with fenofibrate 0.3 g/day, fenofibrate plus colestipol, 15 g/day, and fenofibrate 0.25 g/day plus colestipol. VLDL, LDL, HDL, HDL2, and HDL3 were isolated by ultracentrifugation and precipitation. Lipids and apolipoproteins A–I and B were determined by enzymatic and immunonephelometric techniques, respectively. Administration of fenofibrate alone resulted in decreases in VLDL and LDL cholesterol (−48% and −18%) and in serum apolipoprotein B (−10%), but in increases in HDL, HDL2, and HDL3 (+25%, +26%, and +24%), and in serum apolipoprotein A–I (+6%). Addition of colestipol produced a further reduction in LDL cholesterol (−31%) and in serum apolipoprotein B (−19%). The effects were maintained with less fenofibrate. In FH, an acceptable therapy combines the favourable effects of sufficient lowering of LDL and of a rise in HDL.

Key words

colestipolfenofibratefamilial hypercholesterolaemialipoproteinsserum lipids

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • P. Weisweiler
    • 1
  • W. Merk
    • 1
  • B. Jacob
    • 1
  • P. Schwandt
    • 1
  1. 1.Medical Department II, Grosshadern ClinicUniversity of MunichMunichGermany